HomeBUSINESS
BUSINESS

JCR Starts Development of Another BBB-Penetrating Drug for Hurler Syndrome
(Oct.30.2017)

JCR Pharmaceuticals said on October 26 that it will launch the development of JR-171 (alpha-L iduronidase), a new drug candidate based on its proprietary blood-brain barrier (BBB)-penetrating technology J-Brain Cargo, for the treatment of Hurler syndrome ...
(LOG IN FOR FULL STORY)

News Calendar